CCR9 and neoplasm: So far, we have performed experimental validation on four of the identified candidates (GLIPR1L1, GHSR, CEACAM6, and CCR9, of which we here report on CCR9) using additional tumor cell lines and antigen-specific CTL clones and in all cases we could confirm their immune-modulatory function.